1. Executive Summary

2. Global Biosimilars Market and Forecast to 2021

3. Global Biosimilars Market Share and Forecast to 2021

3.1 Global Biosimilars Market Share and Forecast - By Product Type
3.2 Global Biosimilars Market Share and Forecast - By Applications
3.3 Global Biosimilars Market Share and Forecast - By Country Wise

4. Global Biosimilars Market and Forecast - By Product Type

4.1 Erythropoietin (EPO) Biosimilars Market and Forecast
4.2 Human Growth Hormone (HGH) Biosimilars Market and Forecast
4.3 Granulocyte - Colony Stimulating Factor (G-CSF) Biosimilars Market and Forecast
4.4 Monoclonal Antibody (mAb) Biosimilars Market and Forecast
4.5 Insulin Biosimilars Market and Forecast
4.6 Interferon (IFN) Biosimilars Market and Forecast
4.7 Others Biosimilars Market and Forecast

5. Global Biosimilars Market and Forecast - By Applications

5.1 Oncology Biosimilars Market and Forecast
5.2 Blood Disorders Biosimilars Market and Forecast
5.3 Growth Hormone Deficiencies Biosimilars Market and Forecast
5.4 Chronic and Autoimmune Disorders Biosimilars Market and Forecast
5.5 Other Applications Biosimilars Market and Forecast

6. Global Biosimilars Market and Forecast - By Country Wise

6.1 United States Biosimilars Market and Forecast
6.2 Canada Biosimilars Market and Forecast
6.3 Argentina Biosimilars Market and Forecast
6.4 Germany Biosimilars Market and Forecast

6.4.1 Reimbursement of Biosimilars in Germany

6.5 France Biosimilars Market and Forecast
6.5.1 Reimbursement of Biosimilars in France

6.6 Italy Biosimilars Market and Forecast
6.6.1 Pricing and Reimbursement of Biosimilars in Italy

6.7 Spain Biosimilars Market and Forecast
6.8 United Kingdom Biosimilars Market and Forecast

6.8.1 Reimbursement of Biosimilars in United Kingdom

6.9 China Biosimilars Market and Forecast
6.10 Japan Biosimilars Market and Forecast
6.11 India Biosimilars Market and Forecast
6.12 South Korea Biosimilars Market and Forecast
6.13 Australia Biosimilars Market and Forecast
6.14 Brazil Biosimilars Market and Forecast
6.15 Mexico Biosimilars Market and Forecast
6.16 Rest of the World Biosimilars Market and Forecast

7. Global Biosimilars Company - Profile, Revenue, Approved and Pipeline Biosimilars Analysis

7.1 Biocad

7.1.1 Company Profile
7.1.2 Biocad - Major Biosimilars Approved for Marketing
7.1.3 Biocad - Major Biosimilars in Pipeline

7.2 Celltrion Inc.

7.2.1 Company Profile
7.2.2 Celltrion Inc. - Annual Revenue (2013 - 2015)
7.2.3 Celltrion Inc. - Major Biosimilars Approved for Marketing
7.2.4 Celltrion Inc.- Major Biosimilars in Pipeline

7.3 Dong-A Socio Group

7.3.1 Company Profile
7.3.2 Dong-A Socio Group - Annual Revenue (2014 - 2015)
7.3.3 Dong-A Socio Group - Major Biosimilars in Pipeline

7.4 Pfizer Inc.

7.4.1 Company Profile
7.4.2 Pfizer Inc. - Annual Revenue (2011 - 2015)
7.4.3 Pfizer Inc. - Major Biosimilars Approved for Marketing
7.4.4 Pfizer Inc.- Major Biosimilars in Pipeline

7.5 Intas Pharmaceuticals Ltd.

7.5.1 Company Profile
7.5.2 Intas Pharmaceuticals Ltd. - Annual Revenue (2011 - 2015)
7.5.3 Intas Pharmaceuticals Ltd. - Major Biosimilars Approved for Marketing
7.5.4 Intas Pharmaceuticals Ltd. - Major Biosimilars in Pipeline

7.6 Sandoz International GmbH - A Novartis Company

7.6.1 Company Profile
7.6.2 Sandoz International GmbH - Annual Revenue (2012 - 2015)
7.6.3 Sandoz International GmbH - Major Biosimilars Approved for Marketing
7.6.4 Sandoz International GmbH - Major Biosimilars in Pipeline

7.7 Stada Arzneimittel AG

7.7.1 Company Profile
7.7.2 Stada Arzneimittel AG - Annual Revenue (2011 - 2015)
7.7.3 Stada Arzneimittel AG - Major Biosimilars Approved for Marketing
7.7.4 Stada Arzneimittel AG - Major Biosimilars in Pipeline

7.8 Teva Pharmaceutical Industries Ltd.

7.8.1 Company Profile
7.8.2 Teva Pharmaceutical Industries Ltd. - Annual Revenue (2011 - 2015)
7.8.3 Teva Pharmaceutical Industries Ltd. - Major Biosimilars Approved for Marketing

7.9 Amgen Inc.

7.9.1 Company Profile
7.9.2 Amgen Inc. - Annual Revenue (2011 - 2015)
7.9.3 Amgen Inc. - Major Biosimilars in Pipeline

7.10 Biocon

7.10.1 Company Profile
7.10.2 Biocon - Annual Revenue (2011 - 2015)
7.10.3 Biocon - Major Biosimilars Approved for Marketing
7.10.4 Biocon - Major Biosimilars in Pipeline

7.11 Dr. Reddy's Laboratories

7.11.1 Company Profile
7.11.2 Dr. Reddy's Laboratories - Major Biosimilars Approved for Marketing
7.11.3 Dr. Reddy's Laboratories - Major Biosimilars in Pipeline

7.12 Mylan

7.12.1 Company Profile
7.12.2 Mylan - Annual Revenue (2011 - 2015)
7.12.3 Mylan - Major Biosimilars in Pipeline

7.13 Merck KGaA

7.13.1 Company Profile
7.13.2 Merck KGaA - Annual Revenue (2013 - 2014)
7.13.3 Merck KGaA - Major Biosimilars in Pipeline

8. Biosimilars Approved in Europe

9. Country with Biosimilar Guideline and Published Year

10. Global Biosimilars Market - Driving Factors

10.1 Several Blockbuster Biologics Losing Patent Protection Over the Next Decade
10.2 Growing Geriatric Population and Rising Incidences of Chronic Diseases
10.3 Entry of Biosimilars in the US Market
10.4 Ability to Curb Healthcare Cost
10.5 Clash of Global Titans Brewing in Europe and Emerging Markets
10.6 Drug Delivery Device Companies Hit the Sweet Spot
10.7 Government Initiatives
10.7.1 Initiatives Taken by Government in Various Countries

11. Global Biosimilars Market - Challenges
11.1 Regulatory Issues
11.2 Operational Challenges for Biosimilars
11.3 Biosimilars Manufacturing Challenges


List of Figures:

Figure 2-1: Global - Biosimilars Market (Million US$), 2008 - 2015
Figure 2-2: Global - Forecast for Biosimilars Market (Million US$), 2016 - 2021

Figure 3-1: By Applications - Global Biosimilars Market Share (Percent), 2014 - 2015
Figure 3-2: By Applications - Forecast for Global Biosimilars Market Share (Percent), 2016 - 2021

Figure 4-1: Global - Erythropoietin (EPO) Biosimilars Market (Million US$), 2008 - 2015
Figure 4-2: Global - Forecast for Erythropoietin (EPO) Biosimilars Market (Million US$), 2016 - 2021
Figure 4-3: Global - Human Growth Hormone (HGH) Biosimilars Market (Million US$), 2008 - 2015
Figure 4-4: Global - Forecast for Human Growth Hormone (HGH) Biosimilars Market (Million US$), 2016 - 2021
Figure 4-5: Global - Granulocyte - Colony Stimulating Factor (G-CSF) Biosimilars Market (Million US$), 2009 - 2015
Figure 4-6: Global - Forecast for Granulocyte - Colony Stimulating Factor (G-CSF) Biosimilars Market (Million US$), 2016 - 2021
Figure 4-7: Global - Monoclonal Antibody (mAb) Biosimilars Market (Million US$), 2013 - 2015
Figure 4-8: Global - Forecast for Monoclonal Antibody (mAb) Biosimilars Market (Million US$), 2016 - 2021
Figure 4-9: Global - Insulin Biosimilars Market (Million US$), 2013 - 2015
Figure 4-10: Global - Forecast for Insulin Biosimilars Market (Million US$), 2016 - 2021
Figure 4-11: Global - Interferon (IFN) Biosimilars Market (Million US$), 2014 - 2015
Figure 4-12: Global - Forecast for Interferon (IFN) Biosimilars Market (Million US$), 2016 - 2021
Figure 4-13: Global - Others Biosimilars Market (Million US$), 2013 - 2015
Figure 4-14: Global - Forecast for Others Biosimilars Market (Million US$), 2016 - 2021

Figure 5-1: Global - Oncology Biosimilars Market (Million US$), 2014 - 2015
Figure 5-2: Global - Forecast for Oncology Biosimilars Market (Million US$), 2016 - 2021
Figure 5-3: Global - Blood Disorders Biosimilars Market (Million US$), 2014 - 2015
Figure 5-4: Global - Forecast for Blood Disorders Biosimilars Market (Million US$), 2016 - 2021
Figure 5-5: Global - Growth Hormone Deficiencies Biosimilars Market (Million US$), 2014 - 2015
Figure 5-6: Global - Forecast for Growth Hormone Deficiencies Biosimilars Market (Million US$), 2016 - 2021
Figure 5-7: Global - Chronic and Autoimmune Disorders Biosimilars Market (Million US$), 2014 - 2015
Figure 5-8: Global - Forecast for Chronic and Autoimmune Disorders Biosimilars Market (Million US$), 2016 - 2021
Figure 5-9: Global - Other Applications Biosimilars Market (Million US$), 2014 - 2015
Figure 5-10: Global - Forecast for Other Applications Biosimilars Market (Million US$), 2016 - 2021

Figure 6-1: United States - Biosimilars Market (Million US$), 2014 - 2015
Figure 6-2: United States - Forecast for Biosimilars Market (Million US$), 2016 - 2021
Figure 6-3: Canada - Biosimilars Market (Million US$), 2014 - 2015
Figure 6-4: Canada - Forecast for Biosimilars Market (Million US$), 2016 - 2021
Figure 6-5: Argentina - Biosimilars Market (Million US$), 2014 - 2015
Figure 6-6: Argentina - Forecast for Biosimilars Market (Million US$), 2016 - 2021
Figure 6-7: Germany - Biosimilars Market (Million US$), 2012 - 2015
Figure 6-8: Germany - Forecast for Biosimilars Market (Million US$), 2016 - 2021
Figure 6-9: France - Biosimilars Market (Million US$), 2012 - 2015
Figure 6-10: France - Forecast for Biosimilars Market (Million US$), 2016 - 2021
Figure 6-11: Italy - Biosimilars Market (Million US$), 2012 - 2015
Figure 6-12: Italy - Forecast for Biosimilars Market (Million US$), 2016 - 2021
Figure 6-13: Spain - Biosimilars Market (Million US$), 2012 - 2015
Figure 6-14: Spain - Forecast for Biosimilars Market (Million US$), 2016 - 2021
Figure 6-15: United Kingdom - Biosimilars Market (Million US$), 2012 - 2015
Figure 6-16: United Kingdom - Forecast for Biosimilars Market (Million US$), 2016 - 2021
Figure 6-17: China - Biosimilars Market (Million US$), 2013 - 2015
Figure 6-18: China - Forecast for Biosimilars Market (Million US$), 2016 - 2021
Figure 6-19: Japan - Biosimilars Market (Million US$), 2013 - 2015
Figure 6-20: Japan - Forecast for Biosimilars Market (Million US$), 2016 - 2021
Figure 6-21: India - Biosimilars Market (Million US$), 2013 - 2015
Figure 6-22: India - Forecast for Biosimilars Market (Million US$), 2016 - 2021
Figure 6-23: South Korea - Biosimilars Market (Million US$), 2010 - 2015
Figure 6-24: South Korea - Forecast for Biosimilars Market (Million US$), 2016 - 2021
Figure 6-25: Australia - Biosimilars Market (Million US$), 2014 - 2015
Figure 6-26: Australia - Forecast for Biosimilars Market (Million US$), 2016 - 2021
Figure 6-27: Brazil - Biosimilars Market (Million US$), 2014 - 2015
Figure 6-28: Brazil - Forecast for Biosimilars Market (Million US$), 2016 - 2021
Figure 6-29: Mexico - Biosimilars Market (Million US$), 2014 - 2015
Figure 6-30: Mexico - Forecast for Biosimilars Market (Million US$), 2016 - 2021
Figure 6-31: Rest of the World - Biosimilars Market (Million US$), 2013 - 2015
Figure 6-32: Rest of the World - Forecast for Biosimilars Market (Million US$), 2016 - 2021

Figure 7-1: Celltrion Inc. - Annual Revenue (Million US$), 2013 - 2015
Figure 7-2: Dong-A Socio Group - Annual Revenue (Million US$), 2014 - 2015
Figure 7-3: Pfizer Inc. - Annual Revenue (Million US$), 2011 - 2015
Figure 7-4: Intas Pharmaceuticals Ltd. - Annual Revenue (Million US$), 2011 - 2015
Figure 7-5: Intas Pharmaceuticals Ltd. - Major Biosimilars in Pipeline
Figure 7-6: Sandoz International GmbH - Annual Revenue (Million US$), 2012 - 2015
Figure 7-7: Stada Arzneimittel AG - Annual Revenue (Million US$), 2011 - 2015
Figure 7-8: Teva Pharmaceutical Industries Ltd. - Annual Revenue (Million US$), 2011 - 2015
Figure 7-9: Amgen Inc. - Annual Revenue (Million US$), 2011 - 2015
Figure 7-10: Biocon - Annual Revenue (Million US$), 2011 - 2015
Figure 7-11: Mylan - Annual Revenue (Million US$), 2011 - 2015
Figure 7-12: Merck KGaA - Annual Revenue (Million US$), 2013 - 2014

Figure 10-1: Global - Ageing Population & Forecast (Million), 2010 - 2050

Figure 11-1: The EMA Development and Approval Pathway for Biosimilars


List of Tables:

Table 3-1: By Product Type - Global Biosimilars Market Share (Percent), 2013 - 2015
Table 3-2: By Product Type - Forecast for Global Biosimilars Market Share (Percent), 2016 - 2021dicines Approved and Listed on the Pharmaceutical Benefits Scheme

Table 7-1: Biocad - Major Biosimilars Approved for Marketing
Table 7-2: Biocad - Major Biosimilars in Pipeline
Table 7-3: Celltrion Inc. - Major Biosimilars Approved for Marketing
Table 7-4: Celltrion Inc.- Major Biosimilars in Pipeline
Table 7-5: Dong-A Socio Group - Major Biosimilars in Pipeline
Table 7-6: Pfizer Inc. - Major Biosimilars Approved for Marketing
Table 7-7: Pfizer Inc.- Major Biosimilars in Pipeline
Table 7-8: Intas Pharmaceuticals Ltd. - Major Biosimilars Approved for Marketing
Table 7-9: Sandoz International GmbH - Major Biosimilars Approved for Marketing
Table 7-10: Sandoz International GmbH - Major Biosimilars in Pipeline
Table 7-11: Stada Arzneimittel AG - Major Biosimilars Approved for Marketing
Table 7-12: Stada Arzneimittel AG - Major Biosimilars in Pipeline
Table 7-13: Teva Pharmaceutical Industries Ltd. - Major Biosimilars Approved for Marketing
Table 7-14: Amgen Inc. - Major Biosimilars in Pipeline (Pivotal Trials Phase 3)
Table 7-15: Amgen Inc. - Major Biosimilars in Pipeline
Table 7-16: Biocon - Major Biosimilars Approved for Marketing
Table 7-17: Biocon - Major Biosimilars in Pipeline
Table 7-18: Dr. Reddy's Laboratories - Major Biosimilars Approved for Marketing
Table 7-19: Merck KGaA - Major Biosimilars in Pipeline

Table 8-1: List of EMA Approved Biosimilars - Till May 2016

Table 9-1: List of Countries with Biosimilar Guideline and Published Year

Table 10-1: Europe and US: Major biological Patent Expiries, 2010 - 2020

Companies Mentioned
Biocad, Celltrion Inc., Dong-A Socio Group, Pfizer Inc., Intas Pharmaceuticals Ltd., Sandoz International GmbH - A Novartis Company, Stada Arzneimittel AG, Teva Pharmaceutical Industries Ltd, Amgen Inc., Biocon, Dr. Reddy's Laboratories, Mylan, Merck KGaA